System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Multicenter Study Journal Article Epublish 15 citations

PubMed: 36894916 DOI: 10.1186/s12885-023-10692-x

ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies.

BMC Cancer 23(1):223

Authors: Marion Perréard, Romane Florent, Jordane Divoux, Jean-Michel Grellard, Justine Lequesne, Mélanie Briand, Bénédicte Clarisse, Nathalie Rousseau, Esther Lebreton, Brice Dubois, Valentin Harter, Audrey Lasne-Cardon, Julien Drouet, Alisson Johnson, Anne-Laure Le Page, Céline Bazille, Corinne Jeanne, Martin Figeac, Nicolas Goardon, Dominique Vaur, Emmanuel Micault, Maxime Humbert, Juliette Thariat, Emmanuel Babin, Laurent Poulain, Louis-Bastien Weiswald, Vianney Bastit

Affiliations

  • Normandy University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA laboratory (Precision medicine for ovarian cancers), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.
  • UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.
  • Department of Head and Neck Surgery, Caen University Hospital, Caen, France.
  • Normandy University, UNICAEN, SF Normandy Oncology, US PLATON, ORGAPRED core facility, Caen, France.
  • Clinical Research Department, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.
  • UNICANCER, Comprehensive Cancer Center François Baclesse, Biological Resource Center 'OvaRessources', Caen, France.
  • IRCBN Institut Régional du cancer Basse Normandie, Biological Resource Center 'Tumorotheque de Caen Basse-Normandie', Caen, France.
  • Clinical Research Department, Caen University Hospital, Caen, France.
  • UNICANCER, Comprehensive Cancer Center François Baclesse, North-West Canceropole Data Center, Caen, France.
  • Department of Head and Neck Surgery, UNICANCER, Comprehensive Cancer Center François Baclesse, 3 avenue du Général Harris, Caen, 14000, France.
  • Department of Oral and Maxillofacial Surgery, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.
  • Department of Medical Oncology Surgery, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.
  • Department of Pathology, Caen University Hospital, Caen, France.
  • Department of Biopathology, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.
  • University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France.
  • Department of Cancer Biology and Genetics, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.
  • LPC Caen ENSICAEN/CNRS UMR6534, Caen, France.
  • Normandy University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA laboratory (Precision medicine for ovarian cancers), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.
  • UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.
  • Normandy University, UNICAEN, SF Normandy Oncology, US PLATON, ORGAPRED core facility, Caen, France.
  • UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.
  • Department of Head and Neck Surgery, UNICANCER, Comprehensive Cancer Center François Baclesse, 3 avenue du Général Harris, Caen, 14000, France.

Abstract

BACKGROUND

Radiotherapy is one of the cornerstones of the treatment of Head and Neck Squamous Cell Carcinomas (HNSCC). However, radioresistance is associated with a high risk of recurrence. To propose strategies (such as combinations with drugs) that could over intrinsic radioresistance, it is crucial to predict the response to treatment. Patient-Derived Tumor Organoids (PDTO) are in vitro tridimensional microtumors obtained from patient' own cancer samples. They have been shown to serve as reliable surrogates of the tumor response in patients.

METHODS

The ORGAVADS study is a multicenter observational trial conducted to investigate the feasibility of generating and testing PDTO derived from HNSCC for the evaluation of sensitivity to treatments. PDTO are obtained after dissociation of resected tumors remaining from tissues necessary for the diagnosis. Embedding of tumor cells is then performed in extracellular matrix and culture in medium supplemented with growth factors and inhibitors. Histological and immunohistochemical characterizations are performed to validate the resemblance between PDTO and their original tumor. Response of PDTO to chemotherapy, radiotherapy and innovating combinations are assessed, as well as response to immunotherapy using co-cultures of PDTO with autologous immune cells collected from patient blood samples. Transcriptomic and genetic analyses of PDTO allow validation of the models compared to patients' own tumor and identification of potential predictive biomarkers.

DISCUSSION

This study is designed to develop PDTO models from HNSCC. It will allow comparing the response of PDTO to treatment and the clinical response of the patients from whom they are derived. Our aim is to study the PDTO ability to predict the clinical response to treatment for each patient in view of a personalized medicine as well as to establish a collection of HNSCC models that will be useful for future innovative strategies evaluation.

TRIAL REGISTRATION

NCT04261192, registered February 7, 2020, last amendment v4 accepted on June, 2021.

MeSH

Cells, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell Carcinoma Of Head And Neck, Organoids, Therapeutics

Cited by